Libiam

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Libiam

Property Description
Active ingredient Tibolone (INN)
Form Tablet (Oral dosage form)
Pharmacological class Selective Tissue Estrogenic Activity Regulator (STEAR)
Common use Relief of postmenopausal symptoms (Climacteric syndrome)
Origin Synthetic steroid derivative

What Type of Medicine is Libiam?

Libiam is a prescription-only pharmaceutical preparation whose active ingredient is Tibolone, a synthetic steroid medicine utilized in hormonal therapy. It is classified as a Selective Tissue Estrogenic Activity Regulator (STEAR), a designation that highlights its unique, tissue-specific activity compared to conventional hormonal replacement therapies (HRT). The medicine is clinically recognized for addressing the consequences of postmenopausal estrogen deficiency in women. Libiam is manufactured specifically as an oral dosage form, presented as a tablet for systemic administration.

Composition and Unique Origin of Tibolone

Tibolone, the single active component, is a steroid derivative that functions as a pro-drug after oral ingestion, a feature that differentiates it from direct hormone administration. The compound is rapidly metabolized into three distinct active substances which collectively exert triphasic hormonal activity (estrogenic, progestogenic, and androgenic). This complex mechanism allows the compound to regulate hormonal effects in a tissue-selective manner. The synthetic origin ensures precise chemical control over the triphasic hormonal actions, a key differentiating factor from naturally derived estrogen products.

General Purpose and Benefit

The fundamental benefit of Libiam is the selective modulation of steroid hormone receptors, aiming to restore a balanced hormonal influence in postmenopausal women experiencing symptoms of the climacteric syndrome. The overall purpose of the therapy is to achieve symptomatic relief by addressing the underlying hormonal deficits while targeting specific tissues. Its use is indicated for the treatment of estrogen deficiency symptoms in women more than one year after menopause.

What side effects are possible with Libiam?

Possible Side Effects and Safety Information

The official safety profile of Tibolone (Libiam) organizes potential adverse effects using standard frequency classifications and System Organ Classes (SOC), based on regulatory documentation.

Frequency-Classified Adverse Reactions

Adverse reactions are formally categorized as common (occurring in 1 to 10 out of 100 women) or uncommon (occurring in 1 to 10 out of 1,000 women).

  • Common effects often involve the Reproductive System and Breast Disorders, including vaginal bleeding or spotting, postmenopausal haemorrhage, breast tenderness, and vaginal discharge. Gastrointestinal disorders (lower abdominal pain) and Skin disorders (hirsutism and acne) are also frequently listed. A common finding is also weight increase.
  • Uncommon effects include infections such as vaginal candidiasis and discomfort related to the breast and nipple.

Documented Serious Adverse Reactions

Regulatory safety information notes that the use of Tibolone is associated with an increased risk of specific serious conditions, consistent with other hormone therapies:

  • Malignancy: An increased risk of being diagnosed with endometrial cancer and breast cancer has been documented, with the risk typically increasing with the duration of use.
  • Vascular Events: There is an increased risk of stroke and Venous Thromboembolism (VTE), which includes deep vein thrombosis and pulmonary embolism. The risk of VTE is reported to be highest during the first year of treatment.

Population-Specific Safety Notes

The medicine is contraindicated in patients with a severe liver disorder or a history of liver disorders where function has not returned to normal. Additionally, the overall risk and benefit must be carefully considered in women over 60 years of age, specifically regarding the increased risk of stroke.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Libiam (Tibolone) overdose is primarily defined by the drug's low acute toxicity. Acute over-ingestion of the tablets is formally documented as having a very low acute toxicity in regulatory materials. This classification leads to the regulatory statement that toxic symptoms are generally not expected to occur, even following the simultaneous ingestion of several tablets beyond the prescribed amount. This low-risk assessment is central to the official approach to management and help-seeking guidance.

Documented Manifestations and Emergency Action

Overdose Factor Official Regulatory Statement
Documented Manifestations Clinical signs of over-ingestion are typically confined to the gastrointestinal system and reproductive system, including nausea, vomiting, and unscheduled vaginal bleeding in the female population.
Antidote Status Official prescribing information explicitly states that no specific antidote is known for Tibolone overdose.
Required Management The mandated management procedure is restricted to the provision of symptomatic and supportive treatment as clinically indicated by the patient's presentation.

Seeking Urgent Medical Assistance

Immediate medical attention is required following any suspected over-ingestion for professional assessment, regardless of whether symptoms are currently present. You must seek urgent medical assistance if the officially documented clinical manifestations, such as persistent nausea, vomiting, or unscheduled vaginal bleeding, occur. Regulatory guidance emphasizes that supportive care is the necessary treatment objective for these situations.

Therapeutic Uses of Libiam

What Libiam Treats: Main Uses and Benefits

Libiam (Tibolone) is commonly used to help manage symptoms related to conditions presenting with systemic or localized discomfort due to estrogen deficiency in women who are more than one year postmenopausal. Its therapeutic use provides supportive symptomatic assistance in contexts marked by increased discomfort. It is applied across domains where additional symptomatic support is needed and is relevant for easing symptoms that interfere with daily functioning, as well as addressing the risk of postmenopausal osteoporosis.

The medication may assist with symptoms related to physical discomfort (like hot flushes and night sweats), symptoms related to inflammatory or irritative states (such as vaginal dryness), and symptoms that create noticeable physiological strain (including low mood and libido). In situations where patients experience these multiple symptoms, Libiam helps ease the overall symptom burden and contributes to improved comfort during symptomatic periods.

“Libiam is considered relevant in contexts where symptoms may interfere with emotional and sexual health, and is used when groups of symptoms appear suddenly or fluctuate.”


Quick Fact: Supportive Management for Vasomotor and Urogenital Symptoms

Eligibility and Restrictions for Use

Official Eligibility Rules for Libiam (Tibolone)

Regulatory documents define specific population criteria for the use of Libiam, an oral medication intended for adult postmenopausal women.

Classification Rule (Official Regulatory Wording)
Permitted Population Women who are more than one year after their last natural period [Source 2.1, 2.5]. Treatment may start immediately following surgical menopause [Source 2.1].
Pediatric Use There is no relevant use in the paediatric population (under 18 years of age) [Source 2.7].
Older Adults No dose adjustment is necessary for the elderly, but the decision to prescribe in women over 60 should include consideration of stroke risk [Source 2.1, 3.6].
Renal/Hepatic Status Contraindicated in acute liver disease or history of liver disease where function tests have failed to return to normal [Source 2.7]. Renal impairment is not listed as a contraindication [Source 2.5].
Pregnancy/Lactation Contraindicated during both pregnancy and lactation [Source 2.1, 2.7].

Absolute Contraindications (Must Not Use)

The medicine is absolutely contraindicated for women with a known, past, or suspected history of breast cancer or other oestrogen-dependent malignant tumours. It is also prohibited in women with a history of venous or arterial thromboembolic disease (e.g., DVT, stroke, TIA, myocardial infarction), undiagnosed genital bleeding, untreated endometrial hyperplasia, or certain known thrombophilic disorders [Source 1.1, 1.4, 2.7].

Restricted or Conditional Use

Patients with certain established conditions, including hypertension, diabetes mellitus, endometriosis, or migraine, must be closely supervised during treatment [Source 2.1, 4.3].

What should I know about interactions with other medicines?

Interactions with other medicines and products

Libiam, which contains the active substance tibolone, may interact with other medicinal products by affecting either its own metabolism or the effects of the other drug. This information is based on official governmental regulatory documents.

Interacting Product Category Specific Examples Documented Interaction
Enzyme Inducers Phenobarbital, Phenytoin, Carbamazepine, Rifampicin, Nevirapine, Efavirenz, St. John’s Wort (Hypericum perforatum) These compounds may increase the metabolism of tibolone, potentially leading to a decrease in its therapeutic effect
Anticoagulants Coumarin derivatives (e.g., Warfarin) Tibolone is documented to increase the effect of these anticoagulants due to a decrease in the concentration of anti-thrombin III.

For the combination with coumarin derivatives, the interaction is considered clinically significant, requiring close monitoring of coagulation parameters, such as the International Normalized Ratio (INR). If necessary, the dosage of the anticoagulant should be adjusted by a healthcare professional. The simultaneous use of enzyme-inducing medicines may reduce the efficacy of tibolone. Patients should inform their doctor about all medicines and herbal products they are taking before starting treatment.

Mechanism of Action

Libiam is a monoclonal antibody that specifically modulates bone turnover via interaction with the osteoclast lineage. The compound exhibits high-affinity binding to Receptor R, a transmembrane protein expressed on the surface of pre-osteoclast cells and mature osteoclasts.

This molecular interaction prevents the Receptor R from binding to its natural physiological ligand, thereby interrupting the signaling cascade necessary for osteoclast differentiation and survival. The resultant decrease in the pool of active, mature osteoclasts initiates a local mechanistic cascade within the bone microenvironment. This alters the cellular dynamics of bone remodeling by maintaining the activity of bone-forming cells (osteoblasts) while significantly reducing the rate of bone resorption. This shift in the ratio represents a modulation of the overall physiological processes governing skeletal tissue maintenance.

Dosage and Administration Information

How Libiam is Used: Administration Guidelines

Libiam (Tibolone) is used according to a standardized, continuous regimen focusing strictly on administration protocol rather than clinical outcomes. The medicine is supplied as a 2.5 mg tablet intended solely for oral use.

Dosing and Schedule

The standard prescribed dose is 2.5 mg once daily. The tablet should be taken on a continuous basis, meaning the regimen is not interrupted by scheduled breaks, and intake is ideally performed at the same time every day. The principle guiding the duration of use is to administer the lowest effective dose for the shortest period. The administration is independent of food consumption, but the tablet should be swallowed with some water.

Treatment Initiation and Handling Missed Doses

Specific timing governs when the therapy may commence. Following natural menopause, treatment should be initiated only after at least 12 months have passed since the last natural menstrual bleed. However, following surgical menopause, treatment may begin immediately.

In the event a dose is missed, it should be taken as soon as the user remembers, unless the missed timing is more than 12 hours overdue. If the dose is missed by more than 12 hours, the missed tablet must be skipped, and the next dose taken at its normal scheduled time.

Specific Administration Conditions

No dose adjustment is necessary for older adults. Furthermore, due to the medicine's unique hormonal profile, a separate progestogen must not be added to the Tibolone regimen.

Recent Clinical Evidence

Libiam: Overview of Clinical Studies

This section summarizes the structure of the clinical research describing the clinical evaluation of Libiam for its authorized uses, detailing the types of studies conducted and the outcomes they were designed to measure, according to authoritative sources.


Evidence for Evaluation of Vasomotor Symptoms

Research exploring changes in common postmenopausal symptoms, such as hot flushes and night sweats, has primarily involved short- to medium-term randomized controlled trials (RCTs). These studies compared the measurements taken from Libiam and placebo groups in postmenopausal women with moderate to severe symptoms. Studies reported measurements showing changes in the frequency and severity of hot flushes in the observed populations.

The available research provides insight into short-term changes, but the long-term characteristics of these reported symptomatic patterns beyond the duration of the medium-term clinical trials is not fully established. Reported outcomes for secondary symptoms, such as generalized well-being or mood, showed variability across different studies.


Evidence for Research in Postmenopausal Bone Health

The evidence base involves medium- and long-term trials that examined changes in bone strength. Research focused on measuring Bone Mineral Density (BMD) at the hip and spine, and tracking the occurrence of fractures over extended observation periods. Studies observed BMD measurements, and the data showed patterns related to changes in density scores compared to placebo groups.

Data tracking fracture outcomes are predominantly derived from trials focusing on older women with existing osteoporosis, meaning that results apply only to the populations studied. Therefore, limited information is available for long-term outcomes in early postmenopausal women. Continued observational research remains relevant for monitoring patterns over decades.


What Is Still Uncertain About the Research

Evidence highlights what is known and what is still uncertain about Libiam, acknowledging several recognized research gaps. One area of uncertainty relates to certain secondary outcomes, such as those related to mood or sexual desire, where findings varied across different studies. Furthermore, comparative evidence is limited, as there is limited information from trials that directly compare Libiam against newer, non-steroidal treatments. Certainty remains low when extrapolating the study findings to populations that were not extensively evaluated in the clinical program.

Key Studies & References

  1. The Effects of Tibolone in Older Postmenopausal Women: The LIFT Trial (Long-Term Intervention on Fractures with Tibolone)
  2. Effect of Tibolone on Bone Mineral Density in Postmenopausal Women: Systematic Review and Meta-Analysis
  3. Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data (Relevant for secondary sexual function outcomes comparison)

Frequently Asked Questions (FAQ)

Common questions about Libiam (FAQ)


Q: Are there any common foods or drinks that interact with Libiam?

Official product information indicates that Libiam can be taken independently of food, meaning patients can eat and drink normally while on this treatment. Some patient guidance suggests that for general management of menopausal symptoms like hot flushes, reducing intake of caffeine and alcohol may be helpful. This information focuses on general lifestyle recommendations rather than a specific drug interaction.


Q: Does Libiam affect blood pressure or heart rate?

According to official safety information, Libiam is associated with conditions that require close supervision, such as pre-existing high blood pressure. Furthermore, a large or sudden rise in blood pressure, often accompanied by symptoms like headache or dizziness, is listed as a serious warning sign. If this occurs, the official guidance suggests the treatment should be stopped and medical attention sought immediately.


Q: Is it normal to feel tired or dizzy when first starting Libiam?

Regulatory documents acknowledge that dizziness and tiredness are possible side effects of the medication. The official literature notes that these symptoms may also be related to changes in blood pressure, which require evaluation. Regulatory sources generally advise reporting any new or concerning effects to a healthcare professional.


Q: Can I take simple pain relievers like Tylenol or Advil with Libiam?

Official guidance on drug interactions emphasizes the need for patients to inform their prescribing doctor or pharmacist about all medicines they are taking, including simple pain relievers. This is because the safety of combining Libiam with over-the-counter medications is not always fully documented in clinical trials. It is generally understood that all current treatments should be reviewed with a professional.


Q: What does it mean that Libiam has a 'Boxed Warning' (if applicable)?

Official regulatory documents for tibolone products (Libiam) emphasize serious warnings regarding increased risks of certain conditions, similar to other hormonal therapies. These warnings highlight the documented increased risk of stroke, breast cancer, and endometrial cancer. This prominent placement is intended to emphasize these serious potential risks to both patients and prescribers.


Q: Can I still drink coffee or caffeine while taking Libiam?

Official guidance states that patients can eat and drink normally while taking Libiam. However, certain patient resources suggest that cutting down on caffeine intake may help reduce the frequency and severity of menopausal symptoms like hot flushes. This is described as a general lifestyle recommendation and not a specific interaction warning.


Q: Are headaches a commonly reported side effect of Libiam?

Regulatory documents list headache as a possible side effect of the medication. Additionally, the sudden onset of a severe headache or a new migraine is explicitly described as a serious warning sign. In such cases, official information suggests the medicine should be stopped and immediate medical advice sought.


Q: Does taking Libiam affect driving or operating machinery?

Official regulatory documents state that Libiam has no known effect on a patient’s ability to drive vehicles or operate machinery. Therefore, official sources do not indicate that these activities must be avoided while taking the medication.


Q: Are there any known interactions between Libiam and alcohol?

Official guidance does not list alcohol as a specific substance to be avoided during treatment with Libiam. However, regulatory patient information suggests that reducing alcohol consumption may be helpful for managing menopausal symptoms, such as flushing, and potentially improving sleep quality.


Q: Do official documents mention what happens if someone suddenly stops taking Libiam?

Official patient documents state that if a patient is considering discontinuing treatment, they should discuss this with a doctor. The regulatory documents describe that a professional may suggest reducing the dose gradually over time. This approach is described as potentially helpful in preventing the return of menopausal symptoms.


Q: Can Libiam cause sleep changes like insomnia or vivid dreams?

Regulatory guidance does not explicitly list insomnia or vivid dreams as classified side effects of the medicine itself. However, official resources suggest that general lifestyle changes, such as reducing caffeine and alcohol, are sometimes associated with improved sleep quality during the menopausal transition.


Q: Does Libiam interact with common allergy medications?

Official regulatory guidance requires patients to inform their healthcare professional about all medicines, including common allergy medications, before starting Libiam. This disclosure is important for the professional to evaluate the safety of the combination. The need for this disclosure is emphasized in the product’s official warnings.

How should Libiam be stored and disposed of?

Official Storage and Disposal Requirements

Regulatory documentation defines strict environmental controls for the storage of Libiam (Tibolone) tablets to maintain product stability and shelf life.

Storage Requirement Official Condition (Regulatory Labeling)
Temperature Limit Do not store above 25 C.
Protection Must be protected from light and moisture.
Container Rule Keep the product in the original package or outer carton.
Child Safety Keep out of the sight and reach of children.

Disposal instructions require special attention to environmental safety. The medicine must not be discarded into wastewater systems or household trash. Any unused or expired tablets must be disposed of in accordance with local national requirements, often by returning the product to a pharmacist or designated collection point.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Libiam found in:

A-Z Index: